(Source: Xencor Inc) MONROVIA, Calif., Feb. 18, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that investigators John H. Stone, M.D., Ph.D. from the Massachusetts General Hospital, and Xin Kai, Ph.D. from the Ragon Institute will present the characterization of biomarker assays from Xencor's ongoing, open-label, phase 2 study of XmAb5871 in IgG4-Related Disease (IgG4-RD) at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis, February 18, 2017 at 9:30 a.m. HST (11:30 a.m. PT). The...
↧